Chris O’Brien MD PhD FCCP
Chief Medical Officer Kinaset Therapeutics Inc
Chris joined Kinaset in June 2022, bringing more than 20 years of experience in early and late phase clinical development across inhaled, oral, and biologic therapies. He has led over 25 Phase 2–4 trials and multiple successful NDA, sNDA, and BLA programs across respiratory, inflammatory, and immunologic diseases, including asthma, COPD, IBD, rheumatoid arthritis, and dermatology. Prior to Kinaset, Chris held senior leadership roles at Janssen, Teva, and AstraZeneca, contributing to landmark programs such as Symbicort, Stelara, ProAir RespiClick, Cinqair, and benralizumab. He is a physician scientist trained at the University of Pennsylvania and a Fellow of the College of Chest Physicians.
Seminars
Tuesday 15th September 2026
Unlocking Broad COPD Control with Inhaled JAK Inhibition, Utilizing Targeted Delivery for Safer, More Effective Treatment
11:30 am
- Discover how inhaled pan-JAK inhibition could enable treatment across both eosinophilic and non-eosinophilic COPD phenotypes, expanding reach beyond current biologic limitations
- Explore the benefits of dry powder inhalation delivering therapy to the lungs, enhancing local efficacy while minimizing systemic exposure and improving safety profiles
- Understand how targeted pulmonary delivery of small molecules could provide a convenient, scalable alternative to biologics, supporting better patient adherence and clinical outcomes
